X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1170) 1170
Publication (169) 169
Book Review (21) 21
Book Chapter (14) 14
Report (8) 8
Newspaper Article (6) 6
Magazine Article (4) 4
Conference Proceeding (2) 2
Government Document (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (816) 816
index medicus (795) 795
rituximab (580) 580
male (389) 389
female (381) 381
maintenance (372) 372
middle aged (334) 334
maintenance therapy (319) 319
oncology (315) 315
adult (296) 296
aged (287) 287
cyclophosphamide (269) 269
hematology (268) 268
treatment outcome (248) 248
therapy (190) 190
follicular lymphoma (189) 189
antineoplastic combined chemotherapy protocols - therapeutic use (171) 171
chemotherapy (171) 171
non-hodgkins-lymphoma (163) 163
immunosuppressive agents - therapeutic use (158) 158
rheumatology (158) 158
care and treatment (155) 155
lymphomas (151) 151
antibodies, monoclonal, murine-derived - therapeutic use (144) 144
transplantation (144) 144
remission induction (129) 129
prognosis (127) 127
maintenance chemotherapy (125) 125
cancer (124) 124
lymphoma, follicular - drug therapy (121) 121
antineoplastic agents - therapeutic use (118) 118
randomized-trial (118) 118
analysis (117) 117
lymphoma (117) 117
trial (117) 117
recurrence (115) 115
remission (114) 114
survival (113) 113
immunology (112) 112
immunotherapy (110) 110
aged, 80 and over (109) 109
medicine & public health (106) 106
retrospective studies (106) 106
rituximab maintenance (106) 106
anca-associated vasculitis (103) 103
disease-free survival (103) 103
vasculitis (101) 101
mycophenolate-mofetil (99) 99
antibodies, monoclonal - therapeutic use (98) 98
research (98) 98
drug therapy (97) 97
wegeners-granulomatosis (97) 97
patients (96) 96
antibody-associated vasculitis (92) 92
medicine, general & internal (92) 92
risk factors (88) 88
young adult (88) 88
azathioprine (86) 86
clinical trials (85) 85
cyclophosphamide - therapeutic use (85) 85
rituximab - therapeutic use (85) 85
anti-neutrophil cytoplasmic antibody-associated vasculitis - drug therapy (84) 84
progression-free survival (83) 83
abridged index medicus (82) 82
health aspects (79) 79
pharmacology & pharmacy (78) 78
term-follow-up (76) 76
follow-up studies (75) 75
antibodies, monoclonal, murine-derived - administration & dosage (74) 74
adolescent (70) 70
b-cell lymphoma (69) 69
drug administration schedule (69) 69
antibodies, monoclonal, murine-derived (67) 67
low-grade (67) 67
microscopic polyangiitis (67) 67
animals (65) 65
anti-cd20 monoclonal-antibody (65) 65
efficacy (65) 65
induction (65) 65
phase-ii trial (64) 64
chronic lymphocytic-leukemia (63) 63
cyclophosphamide - administration & dosage (63) 63
granulomatosis with polyangiitis (63) 63
rituximab - administration & dosage (63) 63
urology & nephrology (63) 63
survival analysis (62) 62
randomized controlled trials as topic (61) 61
time factors (61) 61
corticosteroids (59) 59
immunologic factors - therapeutic use (59) 59
1st-line treatment (58) 58
medical research (58) 58
stem-cell transplantation (58) 58
antibodies, monoclonal, murine-derived - adverse effects (57) 57
article (57) 57
follow-up (57) 57
methotrexate (57) 57
relapse (57) 57
maintenance rituximab (56) 56
mantle cell lymphoma (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1147) 1147
German (21) 21
French (18) 18
Spanish (6) 6
Hungarian (2) 2
Japanese (2) 2
Polish (2) 2
Russian (2) 2
Croatian (1) 1
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 773 - 784
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 216 - 225
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4462 - 4469
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2010, Volume 363, Issue 3, pp. 221 - 232
Journal Article
Journal Article